- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Mankind Pharma Limited — Board Meeting, 06-11-2025: Outcome of Board Meeting
06-11-2025 | 04:44 pm
06-11-2025 | 04:44 pm
Mankind Pharma's board approved Q2 & H1 FY25 consolidated results. Q2 revenue hit ₹3,697 Cr, with profit at ₹511.5 Cr and EPS at ₹12.39. The company also confirmed the recent transfer of the Women's Health Portfolio from BSV for ₹797 Cr, effective Nov 1.
No comments yet. Be the first to comment!